CARE About Fibroids Executive Director Jenny Rosenberg quoted in press release about first FDA approved oral medication for the treatment of uterine fibroids in pre-menopausal women
On May 29, 2020, Jenny Rosenberg, Executive Director of CARE About Fibroids, was featured in an announcement from AbbVie and Neurocrine Biosciences on the U.S. Food and Drug Administration's (FDA) approval of ORIAHNN for the management of heavy menstrual bleeding due to uterine fibroids in pre-menopausal women. Rosenberg has been leading CARE About Fibroids' advocacy around the push for investments and advancements in innovative treatments for women suffering from symptomatic fibroids.
"We have heard from women with fibroids across the country who have been hopeful for a treatment with the potential to address their bleeding effectively," said Jenny Rosenberg, executive director of CARE About Fibroids. "The FDA's approval of an oral treatment for women suffering from heavy menstrual bleeding due to uterine fibroids marks a step forward in women's health."
To read the full announcement, click here.
Comments are closed.